- Report
- August 2021
- 73 Pages
Global
From €3200EUR$3,523USD£2,837GBP
- Report
- July 2022
- 518 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- August 2022
- 541 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Drug Pipelines
- June 2021
- 50 Pages
Global
From €3405EUR$3,500USD£2,917GBP
- Report
- December 2023
- 132 Pages
Global
From €924EUR$950USD£792GBP
- Report
- February 2022
- 120 Pages
Global
From €6001EUR$6,168USD£5,141GBP
- Report
- March 2023
- 147 Pages
Global
From €5837EUR$5,999USD£5,000GBP
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more